NCT05720026: Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer |
|
|
| Recruiting | 3 | 560 | RoW | SYSA1901, pertuzumab biosimilar, Pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Docetaxel, Docetaxel injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | HER2-positive Breast Cancer | 08/25 | 02/26 | | |
